McGill University Health Centre
Welcome,         Profile    Billing    Logout  
 277 Trials 
340 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, Site Public
NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Active, not recruiting
N/A
100
US
No Intervention
Takeda
Constipation, Pregnancy
12/25
12/25
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Recruiting
N/A
600
RoW
Takeda
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
01/26
01/26
CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Recruiting
N/A
40
Europe
Takeda
Hereditary Angioedema (HAE)
03/26
03/26
NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy

Recruiting
N/A
616
US
No Intervention
Takeda, The Organization of Teratology Information Specialists
Chronic Constipation
05/26
05/26
BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting
N/A
70
Europe
No Intervention
Takeda
Hodgkin Lymphoma
06/26
06/26
NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation

Recruiting
N/A
12
US
No Intervention
Takeda, UC San Diego Human Milk Research Biorepository
Chronic Constipation
12/26
12/26
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting
N/A
3000
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
01/27
01/27
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
N/A
50
Europe
No intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
06/27
06/27
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting
N/A
600
RoW
Takeda
Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)
11/27
11/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1340
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
Tsoukas, Michael
NCT04972175: Safety and Efficacy of BC LisPram

Recruiting
1
16
Canada
50-Hour Intervention - Rapid Insulin lispro, 50-Hour Intervention - BC LisPram
Michael Tsoukas, Adocia
Type1 Diabetes Mellitus
06/22
06/22
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Active, not recruiting
N/A
335
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24
Koeppe, Erika
CAPS5, NCT02000089: The Cancer of the Pancreas Screening-5 )Study

Recruiting
3
7000
US
Secretin, ChiRhoStim, MRI, MRCP, Tumor marker gene test with CA19-9
Johns Hopkins University, ChiRhoClin, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
10/24
12/25
John, Veena
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT03835819: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting
2
18
US
Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere
Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC
Endometrial Cancer
08/25
08/28
DENALI, NCT05128825: A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
2
102
Europe, US, RoW
ZN-c3, azenosertib
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
04/25
10/25
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
12/24
12/24
Altit, Gabriel
NCT04106479: NIRS in Congenital Heart Defects - Correlation With Echocardiography

Recruiting
N/A
100
Canada
NIRS evaluation
McGill University Health Centre/Research Institute of the McGill University Health Centre, Medtronic
Congenital Heart Defect, Single-ventricle, Coarctation of Aorta, Atrioventricular Canal, Hypoplastic Left Heart, Transposition of Great Vessels, Interrupted Aortic Arch, Tricuspid Atresia, Pulmonary Atresia, Aortic Atresia, Tetralogy of Fallot
04/23
12/24
Spicer, Jonathan
NCT05714891: Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Recruiting
2
27
Canada
JDQ443
Canadian Cancer Trials Group, Novartis
NSCLC
08/26
03/28
DISCONNECT-1, NCT04409925: DISmantling COvid iNduced Neutrophil ExtraCellular Traps

Completed
1
15
Canada
rhDNase I, Pulmozyme
McGill University Health Centre/Research Institute of the McGill University Health Centre, Hamilton Health Sciences Corporation, Hoffmann-La Roche, Exactis Innovation
COVID-19 Infection
04/21
08/21
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
Gregoire, Cara
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
Sharma, Abhinav
NCT05482958: DECIDE-CV Using AI

Recruiting
N/A
126
Canada
HOP watch
McGill University Health Centre/Research Institute of the McGill University Health Centre, HOP-Child Technologies Inc, MedTeq, Boehringer Ingelheim
Type 2 Diabetes
07/25
07/25
Minnella, Enrico M
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Recruiting
3
526
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
10/24
NCT04628481: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Active, not recruiting
3
327
Europe, US, RoW
Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo
Dompé Farmaceutici S.p.A
New-onset type1 Diabetes
03/25
03/26
NCT04899271 / 2020-002966-15: A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Terminated
2
25
Europe, US, RoW
Ladarixin, LDX, Placebo
Dompé Farmaceutici S.p.A
New-onset Type 1 Diabetes
04/23
10/23
NCT05496868: Add-on Reparixin in Adult Patients With ARDS

Recruiting
2
66
Europe, US
Reparixin 600mg, REP, Matching Placebo, Control
Dompé Farmaceutici S.p.A
Acute Respiratory Distress Syndrome, Adult
04/25
05/25
Cheng
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Recruiting
3
320
Europe, Canada, US, RoW
DZD9008, Pemetrexed+carboplatin
Dizal Pharmaceuticals
Non-small Cell Lung Cancer
02/26
10/27
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
NCT04660929: CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Active, not recruiting
1
48
US
CT-0508, Pembrolizumab, Keytruda
Carisma Therapeutics Inc
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
12/24
12/24
NCT05571137: A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

Completed
N/A
118
Europe, Canada, RoW
Takeda
Cytomegalovirus (CMV)
01/24
01/24
Volk, Sarah
STEP-1, NCT04101669: EndoBarrier System Pivotal Trial(Rev E v2)

Recruiting
N/A
240
US
EndoBarrier Liner, EndoBarrier Sleeve, Duodenal-jejunal Bypass Liner (DJBL), Sham
GI Dynamics, Biostatistical Consulting, Inc.
Diabetes type2, Obesity
04/24
04/25
Naccache, Christopher
PATRON, NCT04557501: PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer

Active, not recruiting
3
800
Canada
PSMA PET/CT guided intensification of therapy, Control Arm
Centre hospitalier de l'Université de Montréal (CHUM), Canadian Cancer Society (CCS), Lantheus Medical Imaging, British Columbia Cancer Agency, London Health Sciences Centre, Princess Margaret Hospital, Canada, Tom Baker Cancer Centre, McMaster University, Institute of Health Economics, Canada, Queen's University
Prostate Cancer
01/29
01/29
Jones, Jada
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
TaxRamPem, NCT04340882: Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Recruiting
2
41
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
Emory University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
12/30
Skowronski, Rodrigo
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
Bakir, Mohamed
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
Watts, Charline
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
ImmunoGen, Inc., GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
Moore, Adelyn
2IQP, NCT05785832: A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes

Active, not recruiting
N/A
335
Canada, US
t:slim X2 insulin pump with Control-IQ technology 1.5 and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Tandem Diabetes Care, Inc., Jaeb Center for Health Research
Type 2 Diabetes Treated With Insulin
09/24
09/24
 

Download Options